Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

159.11 0.65 −0.41%

Follow NBIX

Alert me

Market cap: $16.2B
P/E: 23.0×
Fwd P/E: 20.6×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Reportable Segment	2,861	100.00%
Gross margin		98.18%
Operating margin		21.64%
Pre-tax margin		24.66%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Net product sales	2,834 99.07%	2,331 98.95%	1,861 98.60%	1,090 96.17%	994 95.05%	753 95.53%	410 90.78%	117 72.16%	0 0.00%
Collaboration revenues	27 0.93%	25 1.05%	27 1.40%	43 3.83%	52 4.95%	35 4.47%	42 9.22%	45 27.84%	15 100.00%
Revenue	2,861	2,355	1,887	1,134	1,046	788	451	162	15

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	2,861 100.00%	2,355 100.00%	1,887 100.00%	1,489 100.00%
Revenue	2,861	2,355	1,887	1,489

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
CRENESSITY reimbursement coverage for dispensed scripts	Q3 FY2026	80.0%	80.0%	—
CRENESSITY total patient enrollment start forms	Q4 FY2025	431.00	—	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
CRENESSITY reimbursement coverage for dispensed scripts	‡	‡	‡	‡	‡	‡	‡
CRENESSITY total patient enrollment start forms	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.